ACST · Acasti Pharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $462.0K | $568.0K | $955.0K | - | $2.19M | $2.98M | $2.71M | $1.44M | $460.0K | $1.09M |
| SG&A | $1.99M | $1.96M | $2.13M | - | $1.51M | $1.85M | $2.25M | $1.57M | $1.59M | $1.76M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | $2.0K | - | - | - | $1.0K | - | - | $7.0K |
| Operating Income | ($2.45M) | ($2.53M) | ($3.09M) | - | ($3.70M) | ($4.83M) | ($4.96M) | ($3.04M) | ($2.09M) | ($4.45M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | ($605.0K) | ($852.0K) | ($724.0K) | ($208.0K) | ($446.0K) | ($289.0K) |
| Net Income | ($2.31M) | ($938.0K) | ($3.36M) | - | ($4.16M) | ($3.43M) | ($2.62M) | ($2.39M) | ($3.27M) | ($4.02M) |
| EPS - Basic | ($0.14) | ($0.06) | ($0.21) | - | ($0.36) | ($0.30) | ($0.24) | ($0.21) | ($0.43) | ($0.54) |
| EPS - Diluted | ($0.14) | ($0.06) | ($0.21) | - | ($0.36) | ($0.30) | ($0.24) | ($0.21) | ($0.43) | ($0.54) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.67M | $16.86M | $20.00M | $22.13M | $11.05M | $15.15M | $19.39M | $18.55M | $26.99M | $21.63M |
| Accounts Receivable | - | - | - | - | - | - | $398.0K | $959.0K | $837.0K | $837.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $114.0K | $459.0K | $1.34M | $601.0K | $665.0K | $1.68M | $1.55M | $913.0K | $685.0K | $607.0K |
| Current Assets | $19.21M | $17.30M | $20.52M | $22.71M | $11.94M | $16.06M | $20.43M | $26.88M | $28.89M | $23.61M |
| Total Assets | $68.49M | $66.58M | $69.81M | $71.99M | $61.22M | $65.35M | $69.72M | $76.19M | $78.21M | $73.03M |
| Current Liabilities | $1.28M | $1.25M | $2.31M | $1.93M | $1.97M | $2.67M | $2.60M | $1.77M | $1.40M | $1.97M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.60M | $3.76M | $6.25M | $5.38M | $9.09M | $9.21M | $10.35M | $11.51M | $11.46M | $9.02M |
| Stockholders' Equity | $64.89M | $62.82M | $63.55M | $66.61M | $52.14M | $56.13M | $59.36M | $64.68M | $66.75M | $64.01M |
| Retained Earnings | ($227.30M) | ($224.99M) | ($224.05M) | ($220.69M) | ($221.32M) | ($217.17M) | ($213.74M) | ($207.95M) | ($205.56M) | ($202.29M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.80M) | - | - | - | ($3.60M) | - | - | ($6.24M) |
| Investing Cash Flow | - | - | $0 | - | - | - | ($15.0K) | - | - | $0 |
| Financing Cash Flow | - | - | ($327.0K) | - | - | - | - | - | - | $0 |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -3.4% | -1.4% | -4.8% | - | -6.8% | -5.3% | -3.8% | -3.1% | -4.2% | -5.5% |
| Return on equity | -3.6% | -1.5% | -5.3% | - | -8.0% | -6.1% | -4.4% | -3.7% | -4.9% | -6.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 14.96 | 13.89 | 8.87 | 11.77 | 6.06 | 6.01 | 7.86 | 15.19 | 20.68 | 12.01 |
| Quick ratio | 14.96 | 13.89 | 8.87 | 11.77 | 6.06 | 6.01 | 7.86 | 15.19 | 20.68 | 12.01 |
| Cash ratio | 14.54 | 13.54 | 8.64 | 11.47 | 5.61 | 5.67 | 7.46 | 10.48 | 19.32 | 11.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.06 | 1.06 | 1.10 | 1.08 | 1.17 | 1.16 | 1.17 | 1.18 | 1.17 | 1.14 |
| Liabilities / Assets | 0.05 | 0.06 | 0.09 | 0.07 | 0.15 | 0.14 | 0.15 | 0.15 | 0.15 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 33.9% | 47.7% | - | - | -21.7% | -130.9% | -11.4% | - | - | 5.8% |
| Net income growth (YoY) | 44.3% | 72.7% | - | - | -73.8% | -4.9% | 34.9% | - | - | 11.1% |
| EPS growth (YoY) | 61.1% | 80.0% | - | - | -71.4% | 30.2% | 55.6% | - | - | -350.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 24.5% | 11.9% | -4.6% | 12.2% | -19.4% | -15.9% | -7.3% | - | - | -38.7% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Acasti Pharma Inc. against the 5 most active filers in the same SIC group.